A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

215

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
NocturiaProstatic Hyperplasia
Interventions
DRUG

silodosin

α1-adrenergic antagonist

Trial Locations (27)

Unknown

Watson Investigational Site, Huntsville

Watson Investigational Site, Laguna Hills

Watson Investigational Site, San Diego

Watson Investigational Site, Aventura

Watson Investigational Site, Clearwater

Watson Investigational Site, Orlando

Watson Investigational Site, Marietta

Watson Investigational Site, Sandy Springs

Watson Investigational Site, Coeur d'Alene

Watson Investigational Site, West Des Moines

Watson Investigational Site, Paducah

Watson Investigational Site, Greenbelt

Watson Investigational Site, Troy

Watson Investigational Site, Missoula

Watson Investigational Site, Omaha

Watson Investigational Site, Las Vegas

Watson Investigational Site, Lawrenceville

Watson Investigational Site, Albuquerque

Watson Investigational Site, Bay Shore

Watson Investigational Site, New York

Watson Investigational Site, Williamsville

Watson Investigational Site, Concord

Watson Investigational Site, Salisbury

Watson Investigational Site, Bethany

Watson Investigational Site, Bala-Cynwyd

Watson Investigational Site, Myrtle Beach

Watson Investigational Site, Burien

Sponsors
All Listed Sponsors
lead

Watson Pharmaceuticals

INDUSTRY

NCT00793819 - A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia | Biotech Hunter | Biotech Hunter